
Sartorius Stedim Biotech S.A.
SRTOY
Updated: 23/09/2026, 19:10:15
Sartorius Stedim Biotech S.A. operates globally, providing essential instruments and consumables to the biopharmaceutical industry. Their product range is extensive, featuring items such as cell lines, cell culture growth media, and bioreactors. The company also supplies solutions for critical processes like the separation, purification, and concentration of biological materials, alongside systems for the secure storage and transport of both intermediate and final biological products. Furthermore, they offer specialized single-use and reusable hollow-fiber membrane devices, as well as presterilized kits, which are vital for cell and gene therapy applications. Beyond products, Sartorius Stedim Biotech delivers a suite of services covering cell cultivation, fermentation, filtration, purification, and fluid management, in addition to cell harvesting and other sophisticated solutions designed to optimize bioprocesses. They also develop data analytics software to model and improve the workflows involved in biopharmaceutical development and manufacturing. The company caters to a diverse clientele, including pharmaceutical, food, and chemical manufacturers, as well as various research and development institutions. Founded in 1870, Sartorius Stedim Biotech S.A. is headquartered in Aubagne, France, and functions as a subsidiary of Sartorius AG.
No summaries found.
- Share price
- $23.67
- Market cap
- $230.24B
- Exchange
- OTC
- Currency
- USD
- CEO
- Rene Faber
- Employees
- 10,265
- IPO date
- 09/02/2022
- Beta
- 1.136
- Last dividend
- $0.00
- Day range
- $23.23 – $23.67
- 52-week range
- $17.25 – $26.54
- 1-day performance
- 0.40%
- 1-year performance
- 37.19%
- Current drawdown (1Y)
- -10.83%
- CIK
- N/A
- CUSIP
- 80386Y101
- ISIN
- US80386Y1010
- Created
- 07/12/2025, 14:23:06
- Last update
- 23/09/2026, 19:10:15
Track Sartorius Stedim Biotech S.A. with an AI analyst
See which prediction-market events move SRTOY, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.